When assessing the tumor burden in six-month-old mice, IL22-deficient mice indeed possessed significantly less tumor burden than the wild-type control ones, while IL22bp-deficient mice had significantly more tumors than C57BL/6 mice (Figure 1B). This evidence concerns the gene IL22RA2 and neoplasm.